

UN-CONFIRMED MINUTES of a Public meeting of the Board of Directors held at 09:00 on Thursday 1st April 2021 via video conference

Present:	John MacDonald	Chair	JM
	Tim Reddish	Non-Executive Director	TR
	Graham Ward	Non-Executive Director	GW
	Neal Gossage	Non-Executive Director	NG
	Barbara Brady	Non-Executive Director	BB
	Manjeet Gill	Non-Executive Director	MG
	Claire Ward	Non-Executive Director	CW
	Paul Robinson	Chief Financial Officer & Deputy Chief Executive	PR
	Shirley Higginbotham	Director of Corporate Affairs	SH
	Simon Barton	Chief Operating Officer	SB
	Julie Hogg	Chief Nurse	JH
	Emma Challans	Director of Culture and Improvement	EC
	David Selwyn	Medical Director	DS
	Clare Teeney	Director of People	CT
Lorna Branton	Director of Communications	LB	
In Attendance:	Sue Bradshaw	Minutes	
	Robin Smith	Producer for MS Teams Public Broadcast	RS
	Alison Steel	Head of Research & Innovation	AS
	Jane Ferreira	Head of MSK Together, Mid Notts ICP	JF
	Francesca Jones	Ward Sister Ward 21	FJ
	Debra Elleston	Head of Service / Macmillan Lead Nurse for End of Life Care	DE
	Ben Widdowson	Associate Director of Estates & Facilities	BW
Observer:	Donna Broughton	Communications Specialist	
	Ann Mackie	Public Governor	
	Philip Marsh	Public Governor	
	Claire Page	360 Assurance	
	Penny Tindall	Lead Cancer Nurse	
	Tracey Brassington	Community Involvement Manager	
	Sian Bruce		
Apologies:	Richard Mitchell	Chief Executive	RM

The meeting was held via video conference. All participants confirmed they were able to hear each other and were present throughout the meeting, except where indicated.

Item No.	Item	Action	Date
17/922	WELCOME		
1 min	<p>The meeting being quorate, JM declared the meeting open at 09:00 and confirmed that the meeting had been convened in accordance with the Trust's Constitution and Standing Orders.</p> <p>Noting that due to the circumstances with regard to Covid-19 and social distancing compliance, the meeting was held, via video conferencing and was streamed live. This ensured the public were able to access the meeting. The agenda and reports were available on the Trust Website and the public were able to submit questions via the live Q&A function. All participants confirmed they were able to hear each other.</p>		
17/923	DECLARATIONS OF INTEREST		
1 min	There were no declarations of interest pertaining to any items on the agenda		
17/924	APOLOGIES FOR ABSENCE		
1 min	Apologies for absence were received from Richard Mitchell, Chief Executive.		
17/925	MINUTES OF THE PREVIOUS MEETING		
1 min	Following a review of the minutes of the Board of Directors meeting held on 4 th March 2021, the Board of Directors APPROVED the minutes as a true and accurate record.		
17/926	MATTERS ARISING/ACTION LOG		
1 min	The Board of Directors AGREED that actions 17/869, 17/897.1, 17/897.2, 17/897.3, 17/897.4 and 17/900 were complete and could be removed from the action tracker.		
17/927	CHAIR'S REPORT		
6 mins	<p>JM presented the report, which provided an update regarding some of the most noteworthy events and items over the past month from the Chair's perspective, highlighting the staff survey results, HSJ Award for Acute and Specialist Trust of the Year, the Hope Orchard and the Trust's collaboration with HMP Lowdham Grange.</p> <p>JM advised he is going on secondment to University Hospitals of Leicester NHS Trust for one year as Interim Chair. Claire Ward has been appointed as Interim Chair for SFHFT to cover this time. JM expressed thanks to the Board of Directors for their support during his time with the Trust. He said it had been a privilege to work in such a friendly and caring Trust and where, he was sure, high quality care for patients and their families would continue to be provided. He also knew that the Trust would play an increasing role in working with other partners to improve the health of the population and reduce inequalities.</p> <p>The Board of Directors were ASSURED by the report.</p>		

	<p>CT advised it is possible to order vaccine and this is received, but it is often close to the deadline which makes forward planning challenging. While there will be a reduction in overall supply in April, there is enough supply to vaccinate cohorts 1-9 and provide second doses. The impact will be the inability to fully open into cohort 10. The Trust is proactively encouraging people who fall into the eligible categories to book for a vaccine and attend for their second dose.</p> <p>CW queried if there were any themes in relation to 'Did not attends' (DNA) and if they are followed up. In terms of wastage, CW queried how this compares nationally and what lessons have been learnt to minimise wastage. CT advised the largest proportion of DNAs at the hospital hub relate to people who access their second dose elsewhere. This is mainly due to the initial focus of the vaccination programme being on care home staff. However, now the roving programme has been set up people are able to access their second dose away from the hospital hub but this will show as a DNA in the Trust's booking system. All DNAs are followed up.</p> <p>Overall vaccine wastage has been low, with the red line being zero avoidable waste. The more challenging vaccine is Pfizer due to its storage requirements. A system has been set up to communicate across the vaccination centres locally to ensure vaccine is used. It is a flexible programme and there is good communication across the system. This is the same picture nationally. The message is to give vaccine rather than waste it.</p> <p>BB queried if there is a relationship between staff who did not have the flu vaccine and the cohort who are yet to be vaccinated for Covid. CT advised some reasons are the same, for example where there are flexible people in workforce, uptake is not always tracked as the main focus is the substantive workforce. There are other correlations in terms of hesitancy based on cultural differences and myths around vaccines generally, which the Trust has worked hard to dispel. If people are away from the workplace, for example due to sickness or latter stages of pregnancy, etc. there is some overlap, but there is more detailed work to do to fully understand this.</p> <p>DS advised, in terms of wastage, there was an incident early in the vaccination programme whereby a shelf collapsed in a freezer. This was discussed with the manufacturer and the advice was to waste this vaccine.</p> <p>The Board of Directors were ASSURED by the report</p>		
<p>17/929</p>	<p>STRATEGIC PRIORITY 1 – TO PROVIDE OUTSTANDING CARE</p>		
<p>4 mins</p>	<p><u>Maternity Update</u></p> <p>Maternity Perinatal Quality Surveillance Model</p> <p>JH presented the report, highlighting postpartum haemorrhage and the improving response rate to the Friends and Family Test (FFT). There have been 63 incidents this month, all of which resulted in low or no harm. Sadly there have been two stillbirths in month.</p>		

	<p>MG queried how the number of still births in the Trust compares with the national picture. JH advised the Trust performs very well and Nottinghamshire as a county performs well, but much of that is driven by SFHFT.</p> <p>CW advised the monthly maternity safety check meetings continue, as do the visits to the maternity and neonatal units.</p> <p>The Board of Directors were ASSURED by the report</p>		
17/930	STRATEGIC PRIORITY 4 – TO CONTINUOUSLY LEARN AND IMPROVE		
19 mins	<p>AS joined the meeting</p> <p>Research Strategy – Annual Report</p> <p>AS presented the report, highlighting recruitment to studies, finance, patient experience survey and plans for restarting research activity. AS advised most of the research activity over the last year has been in urgent public health studies.</p> <p>SB queried if the time from research to patients feeling the benefit of the research had shortened during Covid and if this is likely to be reflected in other areas. AS advised the hope is sponsors of research have learnt lessons from Covid. One of the priorities in the forthcoming national policy relates to communication between research groups. During Covid it has been demonstrated research teams can be flexible and set up complex studies quickly. There is a need to be sensible in relation to risk.</p> <p>DS advised there has been an improvement in collaboration and streamlining of processes, but advised all the treatments resulting from the studies which have developed as a result of Covid are all off licence, i.e. the full efficacy and risks are not known. The Recovery Study and the REMAP-CAP (Randomised, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia) study are the two studies which have primarily delivered the current treatments for Covid-19. The Trust has been a successful recruiter to the Recovery study.</p> <p>PR expressed thanks to AS and the Research Team for their work.</p> <p>The Board of Directors were ASSURED by the report</p> <p>AS left the meeting</p>		
17/931	STRATEGIC PRIORITY 5 – TO ACHIEVE BETTER VALUE		
22 mins	<p>JF joined the meeting</p> <p>MSK Together service</p> <p>JF gave a presentation highlighting the work of MSK Together.</p>		

NG queried when a plan of actions being taken will be produced and how outcomes will be measured, noting, for example, improving population health; what actions will be taken to achieve that. JF acknowledged measuring healthy life expectancy, which is the upfront outcome within the Integrated Care System (ICS), is difficult. This is often related to EQ-5D, which is a quality of life measure, i.e. if someone reports having a better quality of life, healthy life expectancy also changes. A dashboard is currently being designed and work is underway with the Population Health Team in the ICS. The dashboard will pull together quality of life data, pain data and personal outcomes which will be transferred into years of healthy life expectancy. This can be monitored on a monthly basis. In terms of plans for value improvement projects, there are some rough plans for focus areas. These will include prevention, access to Primary Care services, community, etc. The project plans will evolve as outputs starts to be measured. However, the baseline data is required to inform decisions.

JM noted if savings are to be delivered or efficiency increased, this has to be as result of system wide initiatives, such as MSK Together and queried if this forms part of the benefits matrix. JF advised in terms of allocation of resources, the spend in mid-Nottinghamshire MSK is just under £28m. If this amount of money is allocated for MSK, the service will need to work within that 'envelope' and invest in areas which would have the largest benefit for population outcomes.

BB noted the comment, "Compared to people from the least deprived areas, people from more deprived areas access hospital services 20 years earlier" and queried if this is local evidence or a national statistic. JF advised this is from mid-Nottinghamshire. When access to hospital services were mapped, it showed a stark contrast which is associated with deprivation.

BB queried if equity of outcomes, in terms of impact, has been considered and if this shows a similar pattern. JF advised when outcomes were looked at there was no real change. With the introduction of the MSK hub, the overall volume of activity going into secondary care has reduced but outcomes have not necessarily improved. The hub does not have the capacity to see everyone. Some people go directly to secondary care and some GP practices bypass the hub. The key part of the hub is the shared decision making process. There is work to be done to hone in on outcomes and monitor them. Getting the dashboard in place is critical to moving forward with the project.

DS advised MSK Together feeds into the perioperative care work, noting the end result is not always surgery. MSK patients have a very high incidence of being on strong opioids before they are put on a definitive treatment and there is a high incidence of addiction. There are real financial opportunities, as well as population health opportunities, of changing that and reducing opioid usage.

JF advised MSK is a long term condition for a large proportion of people and can impact negatively on people's quality of life and hence healthy life expectancy.

	<p>SB queried what the Board of Directors can do to help develop the service. JF advised there needs to be an understanding of the different ways of working, agreeing to trial new financial models and visibly support the project.</p> <p>The Board of Directors were ASSURED by the report</p> <p>JF left the meeting</p>		
17/932	PATIENT STORY – FINDING MARION		
20 mins	<p>FJ and DE joined the meeting</p> <p>FJ and DE presented the Patient Story which related to end of life care provided to a couple on Ward 21.</p> <p>MG asked FJ and DE what would be the one piece of advice they would give the Board of Directors in terms of improvement. DE advised she welcomes the opportunities to present to the Board of Directors and acknowledged the trust the leadership team put in people within their roles to 'do the right thing' and ask the right questions at the right time.</p> <p>FJ and DE left the meeting</p>		
17/933	SINGLE OVERSIGHT FRAMEWORK (SOF) MONTHLY PERFORMANCE REPORT		
38 mins	<p>QUALITY CARE</p> <p>JH highlighted Clostridium difficile (c. diff) rate, dementia screening assessment and advised the number of hospital acquired Covid cases has significantly reduced this month.</p> <p>DS advised a process and group has been established to work through cases of a death following hospital acquired Covid.</p> <p>BB queried the timeline for Nervecentre to be introduced for dementia screening. DS advised the rollout of the Nervecentre module has been pushed back due to rolling out other Nervecentre upgrades of significant importance during Covid. It is likely to be the Autumn before this comes on stream.</p> <p>NG queried if there was any update in relation to the Hospital Standardised Mortality Ratio (HSMR) reduction plan and when this will start to yield results. DS advised an update was provided to the Board of Directors and Quality Committee in March 2021. The data timeline outlined in March gave details of immediate actions to be completed within 3 months and some longer term actions with a 6-9 month timeline. While there has been some reduction in HSMR, it is likely to be 12 months before any real change is evident.</p> <p>JM noted in terms of the c. diff rate, some patients had been double counted and some outpatients had been included in the figures and queried if there was any scope for adjustment when there has been an obvious issue with the figures.</p>		

<p>JH advised the Trust has approached the CCG who have advised once the figures are declared, they cannot be amended. Measures are being put in place for the new financial year to ensure figures are reported appropriately.</p> <p>JM advised the Ombudsman's Office have issued a complaints framework and queried what the implications will be for the Trust. JH advised a patient and carer engagement strategy has been drafted which addresses engaging with patients when things do and do not 'go well'. The Quality Committee has had an initial view of this.</p> <p>MG queried what the key mitigations for dementia screening performance are and what the trajectory for improvement is. JH advised the issue with dementia screening relates to the move to the electronic assessment module and the fact the module has not been rolled out within ED and EAU, which is where most of the assessments take place. A paper audit is carried out to ensure assessments are taking place. This shows good results but the assessments are not being transcribed onto Nervecentre. JH advised she was assured assessments are taking place but it is on paper. To help improve compliance, registered nurses across ward areas are being asked to put the assessment onto Nervecentre, pending the rollout to ED and EAU. Referral rates for onward review for patients identified with potential dementia are consistent.</p> <p>JM queried if there was any additional external assurance available from Dr Foster, etc. for the Board of Directors in relation to HSMR. DS advised Dr Foster is not the only commercial company available to help with this work. The team within the Trust have put raw mortality data into a simple system to look at the baseline figures. While there are peaks and troughs within this, the peaks are in Winter, which is to be expected. This provides some assurance but consideration can be given to other sources of external assurance.</p> <p>Action</p> <ul style="list-style-type: none"> • Consider what is appropriate and proportionate in terms of additional assurance in relation to HSMR performance <p>PEOPLE AND CULTURE</p> <p>EC provided an update in relation to the package which is in place to support colleagues' health and wellbeing, highlighting the support for colleagues returning to work in their usual work areas to help the transition, recognition work and continual improvement.</p> <p>CT advised overall sickness absence rate is reducing and highlighted mandatory training, appraisals and the dedicated psychological support which is available and which has been aligned to the Occupational Health Service. Overall Occupational Health activity remains higher than pre-Covid levels, but is reducing.</p> <p>MG queried if there was any analysis of the reasons for occupational health referrals.</p>	<p>DS</p>	<p>06/05/21</p>
---	-----------	-----------------

	<p>CT advised the increase largely relates to queries about Covid, as well as an increase in people experiencing psychological distress. A deep dive into this will be presented to the People, Culture and Improvement Committee in May 2021.</p> <p>JM advised the planning guidance for 2021/2022 has been received. In putting together plans, judgements need to be made about how quickly the Trust can recover, balanced with the fact staff need time to recover. JM felt there is a need to say thank-you to staff little and often and queried if there are plans for this.</p> <p>EC advised there have been discussions in relation to this and plans include reigniting the 'Stars of the Month', recognition work and key professional recognition and awards will run throughout the year.</p> <p>TIMELY CARE</p> <p>SB advised ED performance remains strong and advised there will be changes in terms of the expectations of waiting times and emergency care over the next 6 months. Cancer care is slightly outside the predicted range. Work is underway to redesign the lower gastrointestinal (GI) cancer pathway and an update will be presented to the Board of Directors in July 2021. Elective waiting lists remain relatively stable.</p> <p>Action</p> <ul style="list-style-type: none"> • Update on lower gastrointestinal (GI) cancer pathway redesign work to be presented to the Board of Directors in July <p>JM felt cancer needs to be a focus for the Board of Directors through recovery. NG noted within the planning guidance for 2021/2022 there is a requirement to return to the 62 days Referral to Treatment (RTT) performance of February 2020 within the next financial year and queried if a plan is in place to achieve that. SB advised 62 day RTT performance in February 2020 was 45 patients; current performance is over 100. Therefore, there is work to do. SB advised he would present a performance improvement plan to the Board of Directors.</p> <p>JM noted access measures are changing and felt it would be useful for the Board of Directors to be briefed on those changes. SB advised the changes will be incorporated into the SOF for the first 6 months of the year and the targets will be revised.</p> <p>Action</p> <ul style="list-style-type: none"> • Cancer performance improvement plan to be presented to the Board of Directors • Briefing note of the changes to the access measures to be circulated to members of the Board of Directors <p>BEST VALUE CARE</p> <p>PR outlined the Trust's financial position at the end of Month 11.</p>	<p>SB</p> <p>SB</p> <p>SB</p>	<p>01/07/21</p> <p>03/06/21</p> <p>03/06/21</p>
--	---	-------------------------------	---

	<p>NG advised there is an expected deficit across the ICS for 2020/2021 and this may impact on the plans for 2021/2022.</p> <p>PR advised he had received confirmation on 1st April 2021 of £10.3m additional support for the system. Therefore, the ICS will record a surplus against the submitted plan for year ending 31st March 2021.</p> <p>The Board of Directors CONSIDERED the report.</p>		
17/934	DATA SECURITY PROTECTION TOOLKIT SUBMISSION		
3 mins	<p>PR presented the report, advising the Audit and Assurance Committee have previously approved the submission of the Data Security Protection Toolkit. The Toolkit has been submitted and the Trust has fully met all 111 mandatory evidence items.</p> <p>There have been two incidents which are reportable to the regulators (Information Commissioner's Office) during 2020/2021 and the Trust has had no further action from the regulators after their investigation.</p> <p>The Board of Directors APPROVED the Data Security Protection Toolkit Submission</p>		
17/935	ANNUAL SIGN OFF OF DECLARATIONS OF INTEREST		
2 mins	<p>SH presented the report, advising Declaration of Interests is an annual requirement and the report reflects the work done during 2020/2021. The conflicts of interest register will be published on the Trust website and will include details of people who have registered an interest, people who have made nil declarations and details of people who are non-compliant. It was noted the number of people who are non-compliant increased towards the end of the year due to the number of new starters in Band 7+ roles.</p> <p>For 2020/2021 88 people are non-compliant.</p> <p>GW advised the Audit and Assurance Committee (AAC) closely monitor declarations of interest. In terms of new starters, ensuring people have completed a declaration of interest will form part of the induction process where relevant. To increase compliance rates, individuals who have not declared an interest for more than a year in the last three years and do not declare early in 2021/2022, will be asked to attend AAC to explain why they have not made a declaration.</p> <p>The Board of Directors APPROVED the annual Declarations of Interest report</p>		
17/936	GENDER PAY GAP REPORT		
1 mins	<p>CT presented the report, advising the Trust is required to publish gender pay gap information annually. The report has previously been presented to the People, Culture and Improvement Committee.</p> <p>The Board of Directors APPROVED the Gender pay gap report</p>		

17/937	APPLICATION OF THE TRUST SEAL		
1 mins	<p>SH presented the report, advising the Trust Seal (Seal number 91 and 92) was affixed to two documents on 4th March 2021.</p> <p>The Board of Directors APPROVED the Use of the Trust Seal</p>		
17/938	SFHFT GREEN PLAN 2021-2026		
9 mins	<p>BW joined the meeting</p> <p>BW presented the report, highlighting the Trust's plans in terms of energy emissions, mileage, waste, single use plastics and sustainable procurement. The Plan aligns with the Trust's strategic priority of promotion of local health. A Sustainability Manager has been recruited. It was noted some of the plans will escalate the cost of future capital developments, for example, adoption of green technologies.</p> <p>SB noted the report references the changes Covid has had in terms of travel, with 40% of patients now being seen non-face to face, colleagues working from home, etc. and queried if it was possible to quantify the impact of this. BW advised this should be possible using benchmarks.</p> <p>BB noted the plan covers a range of issues and queried which will be the most challenging to achieve. BW advised the biggest challenge will be in relation to sustainable procurement. For example, it can be cost prohibitive to procure energy in a sustainable way.</p> <p>GW felt there was work to do to identify the potential additional cost of delivering the strategy.</p> <p>JM queried if there has been any discussion at a system level in relation to environmental issues. BW advised limited funding has been provided to the system to align the green plans of each of the providers.</p> <p>NG noted the work to try to assess the impact of people working from home in terms of commuting, but noted the 'flip side' of this is the additional energy costs incurred by individuals who are working from home.</p> <p>The Board of Directors APPROVED the SFHFT Green Plan 2021-2026</p> <p>BW left the meeting</p>		
17/939	ASSURANCE FROM SUB COMMITTEES		
16 mins	<p>Audit and Assurance Committee (AAC)</p> <p>GW presented the report, highlighting Counter Fraud and Internal Audit.</p> <p>Finance Committee</p> <p>NG advised the Committee met on 30th March 2021, with the main discussion relating to planning for 2021/2022. NG outlined the main points of the planning guidance.</p>		

	<p>The Committee also looked at the Financial Improvement Plans for 2021/2022 and reviewed the internal audit report on the integrity of the general ledger.</p> <p>JM queried what information the Board of Directors need to be sighted on before the plans are submitted. PR advised an update will be provided to each Board of Directors meeting held in Private and the Finance Committee will focus on the draft submission when they meet in April 2021.</p> <p>JM felt the Board of Directors need assurance system partners are committed to the plan. PR advised the system allocations and system elective recovery requirements are almost identical to what was included in the Phase 3 Plan, which was submitted in October 2020.</p> <p>NG felt oversight will increasingly be at an ICS level as we move through 2021/2022, noting there is now an ICS Finance Committee.</p> <p>Quality Committee</p> <p>BB presented the report, highlighting the maternity deep dive, improvement plan relating to anticoagulation therapy and the loss of the United Kingdom Accreditation Service (UKAS) Accreditation for Haematology.</p> <p>DS clarified the loss of the UKAS accreditation relates to the Laboratory Haematology Service and not the Haematology Service as a whole.</p> <p>JM queried if the loss of accreditation would impact the operational delivery of the Haematology Laboratory Service. DS advised the quality of the service is not in doubt and there will be no impact for patients. The Trust has declared the loss of accreditation to other regulators. There are external providers who use the laboratory in a commercial way but they have not raised any concerns. The area which may be impacted is research as new research trials require samples to be analysed in a UKAS accredited laboratory. However, it is not yet clear if this will be impacted. The Trust is actively pursuing different avenues to address the required recruitment.</p> <p>People, Culture and Improvement Committee</p> <p>MG presented the report, highlighting the staff survey and the Trust's progress in relation to the NHS People Plan.</p> <p>The Board of Directors were ASSURED by the reports.</p>		
<p>17/940</p>	<p>OUTSTANDING SERVICE – RADIOLOGY</p>		
<p>7 mins</p>	<p>A short video was played highlighting the work of the Radiology Team.</p>		

17/941	COMMUNICATIONS TO WIDER ORGANISATION		
2 mins	<p>The Board of Directors AGREED the following items would be distributed to the wider organisation:</p> <ul style="list-style-type: none"> • HSJ Award • MSK • Research • Patient Story • Transition to restoring services – getting the balance right • Green Plan 		
17/942	ANY OTHER BUSINESS		
3 mins	<p>CW expressed thanks to JM for his leadership during his time at the Trust and wished him well on behalf of the Board of Directors for his secondment to University Hospitals of Leicester NHS Foundation Trust.</p> <p>TR advised the Lord Lieutenant of Nottinghamshire wished to pass on his congratulations to the Trust for winning the HSJ Award for Acute or Specialist Trust of the Year and acknowledged the improvement of the Trust in a short period of time.</p>		
17/943	DATE AND TIME OF NEXT MEETING		
	<p>It was CONFIRMED the next Board of Directors meeting in Public would be held on 6th May 2021 via video conference at 09:00.</p> <p>There being no further business the Chair declared the meeting closed at 12:15.</p>		
17/944	CHAIR DECLARED THE MEETING CLOSED		
	<p>Signed by the Chair as a true record of the meeting, subject to any amendments duly minuted.</p> <p>Claire Ward</p> <p>Chair Date</p>		

17/945	QUESTIONS FROM MEMBERS OF THE PUBLIC PRESENT		
	No questions were raised.		
17/946	BOARD OF DIRECTOR'S RESOLUTION		
1 min	<p>EXCLUSION OF MEMBERS OF THE PUBLIC - Resolution to move to a closed session of the meeting</p> <p>In accordance with Section 1 (2) Public Bodies (Admissions to Meetings) Act 1960, members of the Board are invited to resolve:</p> <p>“That representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest.”</p> <p>Directors AGREED the Board of Director's Resolution.</p>		